Health news
New Virtual Mental Health and Substance Use (MHSU) Program From Compass Health Center Delivers Specialized Care to a Broader Audience, Bridging the Gap in Access to Essential Services
…
KANSAS CITY, Mo., June 15, 2023 (Newswire.com)
–
Dr. Irfan Handoo, a leading expert in psychiatry and renowned provider of transcranial magnetic stimulation (TMS) and IV ketamine treatments, is excited to announce the relocatio…
Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in cancer treatment
NIT Research Logo
…
Inspire Dental Wellness specializes in the non-surgical treatment of craniofacial pain to help patients improve their quality of life.
…
DEXIS IOS Solutions is pleased to announce the expansion of its portfolio and ecosystem through new digital end-to-end workflows. Dental Practitioners can now easily expand their range of services through aligner and d…
Dr. Todd Lanman
SAN FRANCISCO, June 12, 2023 (Newswire.com)
–
Todd Lanman, MD, of Lanman Spinal Neurosurgery and ADR Spinal Restoration Center, gave se…
The leading online ADHD treatment platform brings in Herman, who has more than two decades of managed care and pharmaceutical experience and is one of the leading experts in behavioral health.
…
GAINESVILLE, Fla., June 12, 2023 (Newswire.com)
–
Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”).
“This is an important milestone for Neobiosis and we are excited to be advancing ViXome, a refined product extracted from thoroughly screened and sterile amniotic fluid obtained at the time of c-section of at-term pregnancies, into clinical development,” said Ian A. White, Ph.D., CEO and CSO of Neobiosis. “We are eager to confirm our preclinical data in the clinic and expect to begin enrolling patients in Phase 1 during the second quarter of 2024.”
ViXome, an acellular product derived from amniotic fluid, contains a heterogeneous population of growth factors, cytokines, chemokines, microRNAs and exosomes, which in pre-clinical testing has demonstrated potent immunomodulatory and pro-reparative effects.
The Phase I/IIa study will thoroughly investigate the safety and clinical efficacy of ViXome. Neobiosis products are processed in state-of-the-art, FDA-registered and FDA-inspected cGMP-compliant cleanrooms in Gainesville, FL. Neobiosis performs its research and development (R&D) at the University of Florida (UF) Sid Martin Innovate Biotechnology Institute in Alachua, FL., the world-recognized leader in biotechnology incubation.
“We are excited to be one of the first companies in the US to advance a potential therapeutic for the treatment of a devastating disease that already affects over 300 million people worldwide,” added Dr. White.
About Neobiosis
Neobiosis is a clinical-stage biopharmaceutical company pioneering the development of perinatal tissue-derived therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical needs. By leveraging the biology of birth tissues as a natural source of regenerative and immunomodulatory cells, matrix and exosomes, Neobiosis has developed its proprietary platform to augment the innate properties of homeostasis to create a portfolio of novel therapeutic candidates. Neobiosis is dedicated to transparency, safety and efficacy of all of its products developed under FDA oversight.
Contact Information:
ian white
CEO
3059062345
Original Source:
Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’
Release of Fortifeye Healthy Weight Loss Bundle
Dr. Michael Lange Dr. Michael Lange empowers many on healthy weight loss
…
Oasis Psychiatric Day Program Achieves Prestigious Behavioral Health Care and Human Services Accreditation from The Joint Commission
Oasis PDP Logo…